research Hair today, gone tomorrow
Two drugs, tofacitinib and ruxolitinib, may help regrow hair by activating hair follicles.
Search
for
Sort by
Research
720-750 / 1000+ results 
research Cyproteronacetat zur topischen Therapie androgenabhängiger Erkrankungen
Cyproterone acetate is used for topical treatment of diseases dependent on male hormones.
research This Month in JAAD: October 2021
Oral baricitinib is effective and safe for treating alopecia areata.
research Tapinarof cream for atopic dermatitis: Pharmacokinetics, systemic exposure, and preliminary efficacy/safety results
Tapinarof cream at 1% concentration is effective and better tolerated for treating atopic dermatitis than the 2% concentration.
research A double blind, randomised, vehicle-controlled, safety and tolerance study of topical PSK 3841 solution at 5% administered twice daily over four weeks to healthy Caucasian males with androgenetic alopecia
research Results of stage I in a phase II randomized bilateral comparison of bexarotene 1% topical gel in alopecia areata
Bexarotene 1% topical gel helped some patients with alopecia areata regrow hair.
research Vitiligo-like depigmentation with perifollicular pigment retention in systemic sclerosis treated successfully with suplatast tosilate
Suplatast tosilate successfully treated a woman's systemic sclerosis symptoms.
research SAT-293 Novel Presentation Of A Heterozygous INSR Mutation And Markedly Elevated Testosterone Levels In A Pediatric Patient, A Case Report.
A young patient with unusual insulin resistance and high testosterone levels had a rare INSR gene mutation.
research SYSTEMATIC REVIEW OF ORAL JANUS KINASE INHIBITORS IN ALOPECIA AREATA: INSIGHTS FROM 2020 TO 2025 STUDIES
Oral JAK inhibitors effectively treat alopecia areata and are generally well-tolerated.
research Follicular delivery of spironolactone via nanostructured lipid carriers for management of alopecia
Nanostructured lipid carriers can effectively deliver spironolactone to hair follicles for treating hair loss.
research 41701 Efficacy of the Oral JAK1/JAK2 Inhibitor CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata: Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 Phase 3 Trial
CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.
research Intermittent Low-dose Ritlecitinib in Refractory Paediatric Alopecia Areata: A Case Report with Therapeutic Implications
Low-dose Ritlecitinib may help children with stubborn Alopecia Areata.
research Sulfur Containing Tyrosine Analogs Can Cause Selective Melanocytotoxicity Involving Tyrosinase-Mediated Apoptosis
research REKONDISI TRANSFORMATOR DISTRIBUSI DI UP BANDUNG
The 7.5% talok and 2% pare leaf extract hair tonic effectively promotes hair growth, similar to minoxidil.
research Spironolactone in Dermatology: A Mini Review
Spironolactone may be effective for acne and other skin conditions and could be used more in treatment.
research Sarcoïdose grave
Severe sarcoidosis often requires long-term systemic corticosteroids and multidisciplinary care, with most patients improving but some experiencing persistent symptoms or complications.
research A 5α-reductase inhibitor, finasteride, increases differentiation and proliferation of embryonal carcinoma cell-derived-neural cells
research Oral isotretinoin combined with topical clobetasol 0.05% and tacrolimus 0.1% for the treatment of frontal fibrosing alopecia: a randomized controlled trial
Taking oral isotretinoin with creams worked better for treating a type of hair loss than creams alone.
research SOCS3 treatment prevents the development of alopecia areata by inhibiting CD8+ T cell-mediated autoimmune destruction
SOCS3 treatment can prevent hair loss by stopping harmful immune responses.
research BindingDB Entry 50021519: Discovery of (2S)-N-(6-Cyano-5-(trifluoromethyl)pyridin-3-yl)-3-(6-(4-cyanophenyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)-2-hydroxy-2-methylpropanamide as a Highly Potent and Selective Topical Androgen Receptor Antagonist for Androgenetic Alopecia Treatment.
research 12-O-Tetradecanoylphorbol-13-acetate Induces Apoptosis in Renal Epithelial Cells through a Growth Signal Conflict Which Is Prevented by Activated ras1
Activated ras can protect kidney cells from a certain substance that causes cell death.
research Dipyridamole-Associated Shock and Pulmonary Edema; Oxcarbazepine-Induced Resistant Ventricular Fibrillation; Finasteride-Induced Pseudoporphyria; Suicidal Ideation Associated with Asenapine; Rediscovering Adverse Anticholinergic Effects; Prevalence of Adverse Drug Events in Ambulatory Care
research Canagliflozin alleviates progestin resistance by suppressing RARβ/CRABP2 signaling in THRB knockout endometrial cancer cells
Canagliflozin helps overcome progestin resistance in certain endometrial cancer cells.
research Two cases of alopecia areata treated with ruxolitinib: a discussion of ideal dosing and laboratory monitoring
Ruxolitinib effectively and safely regrows hair in alopecia patients.
research BH02 Overcoming genetic drivers in alopecia areata: hair regrowth in a patient with the AIRE gene mutation treated with ruxolitinib
Ruxolitinib helped a woman with a genetic mutation regrow her hair and improved her health.
research Hair Sciences: Comments on the use of spironolactone in female pattern hair loss
research Metoprolol-spironolactone combination for coronary heart disease with concurrent heart failure: impact on cardiac function
The metoprolol-spironolactone combination improves heart function in patients with coronary heart disease and heart failure.
research SIÇANLARDA SODYUM VALPROAT KAYNAKLI MİDE HASARI ÜZERİNE RUTİN’İN OKSİDATİF STRES, İNFLAMASYON VE APOPTOZ ÜZERİNDEKİ KORUYUCU ETKİLERİNİN ARAŞTIRILMASI
Rutin may protect against stomach damage caused by sodium valproate.
research An excellent response to tofacitinib in a Brazilian adolescent patient with alopecia areata: A case report and a review of the literature
A Brazilian teenager with severe hair loss had total hair regrowth with no side effects after using tofacitinib.
research Safety of 5α-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies
The medications 5α-reductase inhibitors and spironolactone are generally safe for breast cancer patients on endocrine therapies and do not significantly increase breast cancer risk.